

***Fiscal Year 2021 (FY21) Chronic Pain Management Research Program (CPMRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Exploration Award (CEA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-21-CPMRP-CEA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> <li>• Supports proof-of-principle pilot studies, clinical trials, and correlative studies with the potential to resolve current clinical barriers.</li> <li>• Research must address one or both of the FY21 CPMRP CEA Focus Areas of chronification of pain and effectiveness or observational studies of novel or untested techniques/approaches/pathways to chronic pain management.</li> <li>• Preliminary data are not required for FY21 CPMRP CEA applications.</li> <li>• Statistically underpowered studies of efficacy are not pilot studies and will not be supported under the FY21 CPMRP CEA mechanism.</li> <li>• <b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$250,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> July 30, 2021 5:00 p.m. Eastern time</p> <p><b>Application:</b> November 12, 2021 11:59 p.m. Eastern time</p>
<p><b>Investigator-Initiated Research Award (IIRA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-21-CPMRP-IIRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports innovative research that will make an original and important contribution to the field of research, patient care, and/or quality of life.</li> <li>• Research must address one or more of the FY21 CPMRP IIRA Focus Areas of chronification of pain, development of non-opioid therapies and methods for the treatment of chronic pain, and effectiveness or observational studies of novel or untested techniques/approaches/pathways to chronic pain management.</li> <li>• Partnering PI Option is available.</li> <li>• Multidisciplinary collaborations and innovative approaches are encouraged.</li> <li>• Clinical trials will not be funded.</li> <li>• <b><i>Pre-application submission is required; application submission is by invitation only.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$900,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> July 30, 2021 5:00 p.m. Eastern time</p> <p><b>Application:</b> November 12, 2021 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Translational Research Award (TRA)</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>W81XWH-21-CPMRP-TRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports translational research that will accelerate the movement of efficacious, evidence-based ideas into clinical applications.</li> <li>• Research must address one or more of the FY21 CPMRP TRA Focus Areas of implementation science, comparative effectiveness, and observational studies related to chronic pain.</li> <li>• Partnering PI Option is available.</li> <li>• Incorporation of biopsychosocial models of assessment and stakeholder engagement are encouraged.</li> <li>• Studies seeking to evaluate new therapies or approaches, either pharmacological or non-pharmacological, that have not been previously evaluated in a clinical setting will not be funded.</li> <li>• <i>Pre-application submission is required; application submission is by invitation only.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$1,400,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> July 30, 2021 5:00 p.m. Eastern time</p> <p><b>Application:</b> November 12, 2021 11:59 p.m. Eastern time</p>